Trial Profile
A Combined Phase 1/2a, Exploratory Study of a Therapeutic Vaccine Using an Adenovirus Type 26 Vector Prime and Modified Vaccinia Ankara Boost Combination With Mosaic Inserts in HIV-1 Infected Adults Who Initiated Antiretroviral Treatment During Acute HIV Infection
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Mar 2022
Price :
$35
*
At a glance
- Drugs Ad26 Mos HIV (Primary) ; MVA-Mosaic-HIV-vaccine-Janssen-Vaccines-and-Prevention (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Janssen Vaccines and Prevention B.V
- 09 Oct 2018 Status changed from active, no longer recruiting to completed.
- 11 Sep 2018 Planned End Date changed from 18 Sep 2018 to 21 Sep 2018.
- 24 Nov 2017 Status changed from recruiting to active, no longer recruiting.